Evercore ISI lowered the firm’s price target on Boston Scientific (BSX) to $96 from $112 and keeps an Outperform rating on the shares. The company delivered a “solid” Q4 with 12.7% organic growth, though some areas slightly missed expectations, the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $110 from $125 at Stifel
- Boston Scientific price target lowered to $100 from $135 at JPMorgan
- Boston Scientific price target lowered to $94 from $125 at Wells Fargo
- Boston Scientific price target lowered to $99 from $112 at Goldman Sachs
- Boston Scientific price target lowered to $100 from $115 at TD Cowen